Overview
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation for patients with serious diseases and major treatment gaps.
The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for additional immune-related conditions. Spero is applying its clinical development, regulatory, and operational capabilities to build a focused pipeline in immunology and inflammation.